HARVEY J. ALTER, M.D.; PAUL V. HOLLAND, M.D.; ROBERT H. PURCELL, M.D.; JERROLD J. LANDER, M.D.; STEPHEN M. FEINSTONE, M.D.; ANDREW G. MORROW, M.D.; PAUL J. SCHMIDT, M.D.
In a prospective study the exclusion of commercial blood donors and donors positive for hepatitis-B antigen (HBAg) resulted in a hepatitis frequency of only 3.7 cases/1000 units transfused. Residual posttransfusion hepatitis was caused by at least two viruses. Four of 10 cases were short incubation, HBAg negative; six cases were long incubation, HBAg positive. One patient had both diseases in sequence. Some cases of HBAg-positive hepatitis occurred despite the fact that patients received only blood that was HBAg negative by counterelectrophoresis; current tests for HBAg, including radioimmunoassay, cannot detect all donors capable of transmitting HBAg-positive hepatitis. The presence of anti-HBAg in donor blood was common and did not correlate with posttransfusion hepatitis; donors with anti-HBAg should not be excluded.
ALTER HJ, HOLLAND PV, PURCELL RH, LANDER JJ, FEINSTONE SM, MORROW AG, et al. Posttransfusion Hepatitis After Exclusion of Commercial and Hepatitis-B Antigen-Positive Donors. Ann Intern Med. ;77:691–699. doi: 10.7326/0003-4819-77-5-691
Download citation file:
Published: Ann Intern Med. 1972;77(5):691-699.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use